Abstract
Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy that is associated with a partial duplication of human chromosome 17 (CMT subtype 1A). Previously, we generated a transgenic rat model ('CMT rat') of CMT1A by overexpressing the peripheral myelin protein of 22 KDa (PMP22), the responsible disease gene. We used the CMT rat to explore novel therapeutic options in CMT1A. In a proof-of-principle study we identified the progesterone receptor of myelinating Schwann cells as a possible pharmacological target in CMT1A. To more closely mimik the clincial situation of CMT1A patients, we now extended our study to later time points, longer therapy duration and also included female rats in a seperate treatment arm.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
